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To the Editor:
We thank Dr Medford for his interest in our recent article in CHEST (August 2011). 1 Prior studies by our group demonstrated that direct instillation of either Mycoplasma pneumoniae or recombinant M pneumoniae community-acquired respiratory distress syndrome toxin (rCARDS Tx) causes a lymphocytic perivascular response and eventually induces a robust peribronchial infl ammation in both rodents and baboons. 2 More recent studies in our primate model found that rCARDS Tx can initiate a T-helper 2 cell response and "asthma-like" lesions with mixed eosinophilic/lymphocytic infi ltration of airways, mucous metaplasia, and focal mucous plugs (unpublished data). Other groups have shown that allergic airway infl ammation impairs the innate host defenses of the lung and results in reduced clearance of M pneumoniae in animal models of asthma. 3 There are increasing data that both M pneumoniae and CARDS Tx play some role in promoting airway infl ammation that could contribute to the onset and clinical course of asthma.
The fact that macrolide antibiotics may be of therapeutic benefi t in some patients with asthma is not surprising because macrolides belong to a family of compounds that possess both immunomodulatory and antimicrobial activity. The proven effi cacy of macrolide antibiotics in other chronic respiratory conditions, such as diffuse pan-bronchiolitis, bronchiectasis, and cystic fi brosis, 4 has led some physicians to use macrolides in patients with diffi cult to control asthma. However, whether macrolides "treat" occult atypical bacterial infections or reduce infl ammatory processes is unclear. Thus, routine use of macrolide antibiotics in the management of chronic stable asthma cannot be recommended because of the lack of available evidence for their effi cacy. Despite these facts, however, there is increasing evidence that some asthmatic patients may be chronically infected or colonized with atypical bacteria and may benefi t from macrolide therapy. However, it remains unclear how to best identify this group of patients, as well as the appropriate dose, frequency, and duration of therapy required to eradicate these organisms. Clearly, more research is needed to better elucidate the role of atypical bacteria in the pathogenesis of asthma and to better defi ne the antiinfl ammatory mechanisms of macrolide antibiotics. Only then will we be able to assess the therapeutic value of macrolides in chronic asthma. 
Racial Differences Infl uence Health-Related Quality-of-Life Measurements
To the Editor:
I read with interest the article by Han et al 1 in a recent issue of CHEST (November 2011) that shows African Americans with a prior history of COPD exacerbations reported worse healthrelated quality of life (HRQL) than their Caucasian counterparts despite having comparable lung functions. The data analyzed are huge and multi-centered in origin from the United States. In their statistical regression model, this racial factor remains independently associated with worse HRQL, along with several other variables such as dyspnea, age , smoking duration, and education level.
In a much smaller sample of local patients with persistent moderate-to-severe asthmatics, my colleagues and I have previously published that patients of Indian ethnicity, compared with those of Malays or Chinese ethnicity, reported worse HRQL based on the St. George Respiratory Questionnaire. These patients remained independently associated with lower HRQL after adjustment for age, sex, asthma duration, and inhaled corticosteroid dose. 2 In our model of multiple regression using variables identifi ed from factor analysis, education level stood together with Indian ethnicity as being independent associates. Although they studied different airway diseases, both these studies look at the infl uence of racial difference on HRQL of patients with chronic persistent airway diseases.
Han et al 1 rightly discussed this from the perspective of disease exacerbations, and considered factors among African Americans like "experience" of breathlessness, education level, and socio-economic status with implications on health insurance as plausible explanations for worse HRQL. The obvious implication of this is how best to prevent and manage the exacerbations of African Americans. Here, disease exacerbations are perceived as the link to understanding why a particular race of people reports poorer HRQL.
Another important perspective when interpreting racial differences in HRQL fi ndings is to consider HRQL as a measuring tool that lacks the sensitivity to discern infl uence of racial and cultural differences. Many such tools are developed primarily in homogenous, well-educated patient populations that may not be universally interpretable when applied across different cultures and ethnicity. 3 Findings like ours and those of Han et al lend support to such a notion, especially since different ethnic groups can report differing HRQL despite being comparable in lung function and disease severity. The implication from this is whether we can reliably interpret measurements of HRQL across different cultures and ethnicity, for example, in worldwide multi-center studies 4 and draw meaningful conclusions from them. Perhaps we should be mindful of these implications when interpreting HRQL measurements and appreciate that the racial infl uence exists and can be potent. 5 , 6 
